--- schema_version: "secwatch.filing_event.v1" accession: "0001493152-26-017960" form_type: "8-K" ticker: "ENVB" cik: "0000890821" company_name: "Enveric Biosciences, Inc." filed_at: "2026-04-20T23:59:59+00:00" generated_at: "2026-05-15T05:25:53.854981+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.75 calibrated_materiality_score: 0.75 confidence: "high" source: SEC EDGAR --- # Enveric closes $5M private placement of shares and warrants with potential $8.9M additional proceeds ## Summary - Gross proceeds of ~$5M from sale of 2.22M shares/pre-funded warrants; potential $8.9M more if warrants exercised. - Warrants have exercise price of $2.00; Series I expire in 5 yrs, Series J in 18 months post-registration effective date. - H.C. Wainwright acted as placement agent, receiving 7% cash fee, 1% mgmt fee, and place agent warrants. - Proceeds to be used for product development, working capital, and general corporate purposes. - Offering closed on April 17, 2026 at $2.25 per share/warrant unit. ## SEC filing metadata - accession: 0001493152-26-017960 - form_type: 8-K - ticker: ENVB - cik: 0000890821 - company_name: Enveric Biosciences, Inc. - filed_at: 2026-04-20T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.75 - calibrated_materiality_score: 0.75 - confidence: high - sec_items: 1.01, 3.02, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315226017960/0001493152-26-017960-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315226017960/form8-k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001493152-26-017960 - JSON: https://secwatch.observer/filing/0001493152-26-017960.json - Plain text: https://secwatch.observer/filing/0001493152-26-017960.txt ## Source-grounded claims - claim_id: 2c5fd237a8cde59079f42a5213679806927642b3 claim: Enveric Biosciences, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC with H.C. Wainwright & Co., LLC valued at Cash fee of 7.0% of aggregate gross proceeds plus management fee of 1.0% and expense reimbursement; (effective 2024-12-08). evidence_excerpt: H.C. Wainwright & Co., LLC (the “Placement Agent”) acted as the exclusive placement agent in connection with the Private Placement under an Engagement Letter, dated as of December 8, 2024, as amended on January 14, 2025, June 5, 2025, November 10, 2025, and December 16, 2025 (the “Engagement Letter”). evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315226017960/0001493152-26-017960-index.htm - claim_id: 66051683ec6748824b5f062e4a1ae508c06b0b9b claim: Enveric Biosciences, Inc. entered into Registration Rights Agreement with each Investor valued at Company agreed to file resale registration statement within 15 days and use best efforts to have it (effective 2026-04-16). evidence_excerpt: In connection with the Private Placement, the Company also entered into a registration rights agreement (the “Registration Rights Agreement”), dated as of April 16, 2026, with each Investor, pursuant to which the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission registering the resale of Shares, Pre-Funded Warrant Shares, and Warrant Shares, no later than 15 days after the date of the Registration Rights Agreement, and to use best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 45 days following the date of the Registration Rights Agreement (or 75 days following the date of the Registration Rights Agreement in the event of a “full review” by the Securities and Exchange Commission). evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315226017960/0001493152-26-017960-index.htm - claim_id: f0aa6cd183990b7ef1024b0c685c540f3e523d43 claim: Enveric Biosciences, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at $5.0 million gross proceeds expected, with potential for up to $8.9 million additional upon exercise (effective 2026-04-16). evidence_excerpt: On April 16, 2026, Enveric Biosciences, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors” and each, an “Investor”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “Private Placement”) (i) 98,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,124,223 shares of Common Stock (the “Pre-Funded Warrant Shares”), (iii) Series I warrants to purchase up to 2,222,223 shares of Common Stock (the “Series I Warrants,” and the shares issuable upon exercise thereof, the “Series I Warrant Shares”), and (iv) Series J warrants to purchase up to 2,222,223 shares of Common Stock (the “Series J Warrants,” together with the Series I Warrants, the “Warrants” and the shares issuable upon exercise ther evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315226017960/0001493152-26-017960-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.